What is Kadcyla (ado-trastuzumab emtansine), and how does it work?
Metastatic Breast Cancer (MBC)
Kadcyla (ado-trastuzumab emtansine), as a single agent, is indicated for the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either:
- Received prior therapy for metastatic disease, or
- Developed disease recurrence during or within six months of completing adjuvant therapy.
Select patients for therapy based on an FDA-approved companion diagnostic for Kadcyla.
Early Breast Cancer (EBC)
Kadcyla, as a single agent, is indicated for the adjuvant treatment of patients with HER2-positive early breast cancer who have residual invasive disease after neoadjuvant taxane and trastuzumab -based treatment.
Select patients for therapy based on an FDA-approved companion diagnostic for Kadcyla.
What are the side effects of Kadcyla?
Hepatotoxicity
- Inform patients of the possibility of severe liver injury and advise patients to immediately seek medical attention if they experience symptoms of acute hepatitis such as nausea, vomiting, abdominal pain (especially RUQ abdominal pain), jaundice, dark urine, generalized pruritus, anorexia, etc..
Left Ventricular Dysfunction
- Advise patients to contact a health care professional immediately for any of the following: new onset or worsening shortness of breath, cough, swelling of the ankles/legs, palpitations, weight gain of more than 5 pounds in 24 hours, dizziness or loss of consciousness.
Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The data reflect exposure to Kadcyla as a single agent at 3.6 mg/kg given as an intravenous infusion every 3 weeks (21-day cycle) in 1624 patients including 884 patients with HER2-positive metastatic breast cancer and 740 patients with HER2-positive early breast cancer (Katherine trial).
Metastatic Breast Cancer
In clinical trials, Kadcyla has been evaluated as single-agent in 884 patients with HER2-positive metastatic breast cancer. The most common (≥ 25%) adverse reactions were fatigue, nausea, musculoskeletal pain, hemorrhage, thrombocytopenia, headache, increased transaminases, constipation and epistaxis.
The adverse reactions described in Table 3 were identified in patients with HER2-positive metastatic breast cancer treated in the Emilia trial [see Clinical Studies]. Patients were randomized to receive Kadcyla or lapatinib plus capecitabine. The median duration of study treatment was 7.6 months for patients in the Kadcyla-treated group and 5.5 months and 5.3 months for patients treated with lapatinib and capecitabine, respectively.
In the Emilia trial, 43% of patients experienced Grade ≥ 3 adverse reactions in the Kadcyla-treated group compared with 59% of patients in the lapatinib plus capecitabine-treated group.
Dose adjustments for Kadcyla were permitted . Thirty-two patients (7%) discontinued Kadcyla due to an adverse reaction, compared with 41 patients (8%) who discontinued lapatinib, and 51 patients (10%) who discontinued capecitabine due to an adverse reaction. The most common adverse reactions leading to Kadcyla discontinuation were thrombocytopenia and increased transaminases. Eighty patients (16%) treated with Kadcyla had adverse reactions leading to dose reductions. The most frequent adverse reactions leading to dose reduction of Kadcyla (in ≥ 1% of patients) included thrombocytopenia, increased transaminases, and peripheral neuropathy. Adverse reactions that led to dose delays occurred in 116 (24%) of Kadcyla treated patients. The most frequent adverse reactions leading to a dose delay of Kadcyla (in ≥ 1% of patients) were neutropenia, thrombocytopenia, leukopenia, fatigue, increased transaminases and pyrexia.
Table 3 reports the adverse reactions that occurred in patients in the Kadcyla-treated group (n=490) of the Emilia trial. Selected laboratory abnormalities are shown in Table 4. The most common adverse reactions seen with Kadcyla in the randomized trial (frequency > 25%) were nausea, fatigue, musculoskeletal pain, hemorrhage, thrombocytopenia, increased transaminases, headache, and constipation. The most common NCI-CTCAE (version 3) Grade ≥ 3 adverse reactions (frequency > 2%) were thrombocytopenia, increased transaminases, anemia, hypokalemia, peripheral neuropathy and fatigue.
Table 3 : Adverse Reactions Occurring in ≥ 10% of Patients on the Kadcyla Treatment Arm in the Emilia Trial1
Adverse Reactions | Kadcyla (3.6 mg/kg) n=490 | Lapatinib (1250 mg) + Capecitabine (2000 mg/m²) n=488 | ||
All Grades (%) | Grade 3 - 4 (%) | All Grades (%) | Grade 3 - 4 (%) | |
Blood and Lymphatic System Disorders | ||||
Thrombocytopenia | 31 | 15 | 3.3 | 0.4 |
Anemia | 14 | 4.1 | 11 | 2.5 |
Gastrointestinal Disorders | ||||
Nausea | 40 | 0.8 | 45 | 2.5 |
Constipation | 27 | 0.4 | 11 | 0 |
Diarrhea | 24 | 1.6 | 80 | 21 |
Vomiting | 19 | 0.8 | 30 | 4.5 |
Abdominal pain | 19 | 0.8 | 18 | 1.6 |
Dry Mouth | 17 | 0 | 4.9 | 0.2 |
Stomatitis | 14 | 0.2 | 33 | 2.5 |
General Disorders and Administration | ||||
Fatigue | 36 | 2.5 | 28 | 3.5 |
Pyrexia | 19 | 0.2 | 8 | 0.4 |
Asthenia | 18 | 0.4 | 18 | 1.6 |
Investigations | ||||
Transaminases increased | 29 | 8.0 | 14 | 2.5 |
Metabolism and Nutrition Disorders | ||||
Hypokalemia | 10 | 2.7 | 9 | 4.7 |
Musculoskeletal and Connective Tissue Disorders | ||||
Musculoskeletal pain | 36 | 1.8 | 31 | 1.4 |
Arthralgia | 19 | 0.6 | 8 | 0 |
Myalgia | 14 | 0.6 | 3.7 | 0 |
Nervous System Disorders | ||||
Headache | 28 | 0.8 | 15 | 0.8 |
Peripheral neuropathy | 21 | 2.2 | 14 | 0.2 |
Dizziness | 10 | 0.4 | 11 | 0.2 |
Psychiatric Disorders | ||||
Insomnia | 12 | 0.4 | 9 | 0.2 |
Respiratory, Thoracic, and Mediastinal Disorders | ||||
Epistaxis | 23 | 0.2 | 8 | 0 |
Cough | 18 | 0.2 | 13 | 0.2 |
Dyspnea | 12 | 0.8 | 8 | 0.4 |
Skin and Subcutaneous Tissue Disorders | ||||
Rash | 12 | 0 | 28 | 1.8 |
Vascular Disorders | ||||
Hemorrhage | 32 | 1.8 | 16 | 0.8 |
1 Grouped terms were used for the following Adverse Reactions: Thrombocytopenia: thrombocytopenia, platelet count decreased Anemia: anemia, hemoglobin decreased Abdominal pain: abdominal pain, abdominal pain upper Stomatitis: stomatitis, mucosal inflammation, oropharyngeal pain Transaminases Increased: transaminases increased, aspartate aminotransferase increased, alanine aminotransferase increased, gamma-glutamyltransferase increased, liver function test abnormal, hepatic enzyme increased, hepatic function abnormal Hypokalemia: hypokalemia, blood potassium decreased Musculoskeletal Pain: muscle spasms, musculoskeletal discomfort, musculoskeletal chest pain, back pain, pain in extremity, bone pain, musculoskeletal pain Peripheral neuropathy: neuropathy peripheral, peripheral sensory neuropathy, peripheral motor neuropathy, paresthesia Hemorrhage: Hemorrhage terms (excl laboratory terms) (SMQ, wide), Hemorrhage laboratory terms (SMQ, narrow). SMQ=standardized MedDRA queries |
The following clinically relevant adverse reactions were reported in < 10% of patients in the Kadcyla-treated group in Emilia: dyspepsia (9%), urinary tract infection (9%), chills (8%), dysgeusia (8%), neutropenia (7%), peripheral edema (7%), pruritus (6%), hypertension (5%), blood alkaline phosphatase increased (4.7%), vision blurred (4.5%), conjunctivitis (3.9%), dry eye (3.9%), lacrimation increased (3.3%), drug hypersensitivity (2.2%), left ventricular dysfunction (1.8%), infusion-related reaction (1.4%), pneumonitis (1.2%), nodular regenerative hyperplasia (0.4%), portal hypertension (0.4%).
Table 4 :Selected Laboratory Abnormalities (Emilia)
Parameter | Kadcyla (3.6 mg/kg) | Lapatinib (1250 mg) + Capecitabine (2000 mg/m²) | ||||
All Grades (%) | Grade 3 (%) | Grade 4 (%) | All Grades (%) | Grade 3 (%) | Grade 4 (%) | |
Chemistry | ||||||
Increased AST | 98 | 7 | 0.5 | 65 | 3 | 0 |
Increased ALT | 82 | 5 | 0.2 | 54 | 3 | 0 |
Decreased potassium | 33 | 3 | 0 | 31 | 6 | 0.8 |
Increased bilirubin | 17 | 0.6 | 0 | 57 | 2 | 0 |
Hematology | ||||||
Decreased platelet count | 83 | 14 | 3 | 21 | 0.4 | 0.6 |
Decreased hemoglobin | 60 | 4 | 1 | 64 | 3 | 0.2 |
Decreased neutrophils | 39 | 3 | 0.6 | 38 | 6 | 2 |
Early Breast Cancer
Kadcyla has been evaluated as a single-agent in 740 patients with HER2-positive early breast cancer.
The adverse reactions described in Table 5 were identified in patients with HER2-positive early breast cancer treated in the Katherine trial. Patients were randomized to receive Kadcyla or trastuzumab. The median duration of study treatment was 10 months for patients in the Kadcyla-treated group and 10 months for patients treated with trastuzumab.
One hundred and ninety (26%) patients experienced Grade ≥ 3 adverse reactions in the Kadcyla-treated group compared with 111 (15%) patients in the trastuzumab group. One hundred and thirty-three patients (18%) discontinued Kadcyla due to an adverse reaction, compared with 15 patients (2.1%) who discontinued trastuzumab due to an adverse reaction.
The most common adverse reactions leading to Kadcyla discontinuation (in ≥ 1% of patients) were platelet count decreased, blood bilirubin increased, ejection fraction decreased, AST increased, ALT increased, and peripheral neuropathy.
Dose adjustments for Kadcyla were permitted. One hundred and six patients (14%) treated with Kadcyla had dose reductions. The most frequent adverse reactions leading to dose reduction of Kadcyla (in ≥ 1% of patients) included thrombocytopenia, increased transaminases, blood bilirubin and fatigue. Adverse reactions that led to dose delays occurred in 106 (14%) of Kadcyla treated patients. The most frequent adverse reactions leading to a dose delay of Kadcyla (in ≥ 1% of patients) were neutropenia, thrombocytopenia and AST increased.
Selected laboratory abnormalities are shown in Table 6. The most common adverse reactions seen with Kadcyla in the randomized trial (frequency > 25%) were fatigue, nausea, increased transaminases, musculoskeletal pain, hemorrhage, thrombocytopenia, headache, peripheral neuropathy, and arthralgia.
The most common NCI-CTCAE (version 3) Grade ≥ 3 adverse reactions (> 2%) were thrombocytopenia and hypertension.
Table 5 : Adverse Reactions Occurring in ≥ 10% of Patients in the Katherine Trial1
Adverse Reactions | Kadcyla n=740 | Trastuzumab n=720 | ||
All grades (%) | Grade 3 - 4 (%) | All grades (%) | Grade 3 - 4 (%) | |
Blood and Lymphatic System Disorders | ||||
Thrombocytopenia | 29 | 6 | 2.4 | 0.3 |
Anemia | 10 | 1.1 | 9 | 0.1 |
Gastrointestinal Disorders | ||||
Nausea | 42 | 0.5 | 13 | 0.3 |
Constipation | 17 | 0.1 | 8 | 0 |
Stomatitis | 15 | 0.1 | 8 | 0.1 |
Vomiting | 15 | 0.5 | 5 | 0.3 |
Dry Mouth | 14 | 0.1 | 1.3 | 0 |
Diarrhea | 12 | 0.8 | 13 | 0.3 |
Abdominal pain | 11 | 0.4 | 7 | 0.3 |
General Disorders and Administration | ||||
Fatigue | 50 | 1.1 | 34 | 0.1 |
Pyrexia | 10 | 0 | 4 | 0 |
Infections and Infestations | ||||
Urinary tract infection | 10 | 0.3 | 6 | 0.1 |
Investigations | ||||
Transaminases increased | 32 | 1.5 | 8 | 0.4 |
Musculoskeletal and Connective Tissue Disorders | ||||
Musculoskeletal pain | 30 | 0.7 | 29 | 0.7 |
Arthralgia | 26 | 0.1 | 21 | 0 |
Myalgia | 15 | 0.4 | 11 | 0 |
Nervous System Disorders | ||||
Headache | 28 | 0 | 17 | 0.1 |
Peripheral neuropathy | 28 | 1.6 | 14 | 0.1 |
Dizziness | 10 | 0.1 | 8 | 0.3 |
Psychiatric Disorders | ||||
Insomnia | 14 | 0 | 12 | 0.1 |
Respiratory, Thoracic, and Mediastinal Disorders | ||||
Epistaxis | 22 | 0 | 3.5 | 0 |
Cough | 14 | 0.1 | 12 | 0 |
Vascular Disorders | ||||
Hemorrhage | 29 | 0.4* | 10 | 0.3 |
1 Grouped terms were used for the following Adverse Reactions: Thrombocytopenia: thrombocytopenia, platelet count decreased Anemia: anemia, hemoglobin decreased Stomatitis: stomatitis, mucosal inflammation, oropharyngeal pain Abdominal pain: abdominal pain, abdominal pain upper Urinary Tract Infection: urinary tract infection, cystitis Transaminases Increased: transaminases increased, aspartate aminotransferase increased, alanine aminotransferase increased, gamma-glutamyltransferase increased, liver function test abnormal, hepatic enzyme increased, hepatic function abnormal Musculoskeletal Pain: muscle spasms, musculoskeletal discomfort, musculoskeletal chest pain, back pain, pain in extremity, bone pain, musculoskeletal pain Peripheral neuropathy: neuropathy peripheral, peripheral sensory neuropathy, peripheral motor neuropathy, paresthesia Hemorrhage: Hemorrhage terms (excl laboratory terms) (SMQ, wide), Hemorrhage laboratory terms (SMQ, narrow) *Included one fatal hemorrhage. SMQ=standardized MedDRA queries |
The following clinically relevant adverse reactions were reported in < 10% of patients in the Kadcyla-treated group in Katherine: blood alkaline phosphatase increased (8%), dysgeusia (8%), dyspnea (8%), neutropenia (8%), blood bilirubin increased (7%), hypokalemia (7%), pruritus (7%), hypertension (6%), lacrimation increased (6%), chills (5%), dry eye (4.5%), dyspepsia (4.3%), peripheral edema (3.9%),vision blurred (3.9%), conjunctivitis (3.5%), left ventricular dysfunction (3.0%), drug hypersensitivity (2.7%), infusion-related reaction (1.6%), radiation pneumonitis (1.5%), pneumonitis (1.1%), rash (1.1%), asthenia (0.4%), nodular regenerative hyperplasia (0.3%).
Table 6 : Selected Laboratory Abnormalities (Katherine)
Parameter | Kadcyla n=740 | Trastuzumab n=720 | ||||
All Grade (%) | Grade 3 (%) | Grade 4 (%) | All Grade (%) | Grade 3 (%) | Grade 4 (%) | |
Chemistry | ||||||
Increased AST | 79 | 0.8 | 0 | 21 | 0.1 | 0 |
Increased ALT | 55 | 0.7 | 0 | 21 | 0.1 | 0 |
Decreased potassium | 26 | 2 | 0.5 | 9 | 0.7 | 0.1 |
Increased bilirubin | 12 | 0 | 0 | 4 | 0.7 | 0 |
Hematology | ||||||
Decreased platelet count | 51 | 4 | 2 | 13 | 0.1 | 0.1 |
Decreased hemoglobin | 31 | 1 | 0 | 29 | 0.3 | 0 |
Decreased neutrophils | 24 | 1 | 0 | 19 | 0.6 | 0.6 |
Immunogenicity
As with all therapeutic proteins, there is the potential for an immune response to Kadcyla. A total of 1243 patients from seven clinical studies were tested at multiple time points for anti-drug antibody (ADA) responses to Kadcyla. Following Kadcyla dosing, 5.1% (63/1243) of patients tested positive for anti-Kadcyla antibodies at one or more post-dose time points. In clinical studies, 6.4% (24/376) of patients tested positive for anti-Kadcyla antibodies. In Emilia, 5.2% (24/466) of patients tested positive for anti-Kadcyla antibodies, of which 13 were also positive for neutralizing antibodies. In Katherine, 3.7% (15/401) of patients tested positive for anti-Kadcyla antibodies, of which 5 were also positive for neutralizing antibodies. Due to the low incidence of ADA, conclusions cannot be made on the impact of anti-Kadcyla antibodies on the pharmacokinetics, safety, and efficacy of Kadcyla. The presence of Kadcyla in patient serum at the time of ADA sampling may interfere with the ability of this assay to detect anti-Kadcyla antibodies. As a result, data may not accurately reflect the true incidence of anti-Kadcyla antibody development. Immunogenicity data are highly dependent on the sensitivity and specificity of the test methods used. Additionally, the observed incidence of a positive result in a test method may be influenced by several factors, including sample handling, timing of sample collection, drug interference, concomitant medication and the underlying disease. Therefore, comparison of the incidence of antibodies to Kadcyla with the incidence of antibodies to other products may be misleading. Clinical significance of anti-Kadcyla antibodies is not yet known.

SLIDESHOW
Breast Cancer Awareness: Symptoms, Diagnosis, and Treatment See SlideshowWhat is the dosage for Kadcyla?
Patient Selection
Select patients based on HER2 protein overexpression or HER2 gene amplification in tumor specimens. Assessment of HER2 protein overexpression and/or HER2 gene amplification should be performed using FDA-approved tests specific for breast cancers by laboratories with demonstrated proficiency. Information on the FDA-approved tests for the detection of HER2 protein overexpression and HER2 gene amplification is available at: http://www.fda.gov/CompanionDiagnostics.
Improper assay performance, including use of sub-optimally fixed tissue, failure to utilize specified reagents, deviation from specific assay instructions, and failure to include appropriate controls for assay validation, can lead to unreliable results.
Recommended Doses And Schedules
Do not substitute trastuzumab for or with Kadcyla.
- The recommended dose of Kadcyla is 3.6 mg/kg given as an intravenous infusion every 3 weeks (21day cycle). Do not administer Kadcyla at doses greater than 3.6 mg/kg.
- Closely monitor the infusion site for possible subcutaneous infiltration during drug administration.
- First infusion: Administer infusion over 90 minutes. Observe patients during the infusion and for at least 90 minutes following the initial dose for fever, chills, or other infusion-related reactions.
- Subsequent infusions: Administer over 30 minutes if prior infusions were well tolerated. Observe patients during the infusion and for at least 30 minutes after infusion.
Metastatic Breast Cancer (MBC)
Patients with MBC should receive treatment until disease progression or unmanageable toxicity.
Early Breast Cancer (EBC)
Patients with EBC should receive treatment for a total of 14 cycles unless there is disease recurrence or unmanageable toxicity.
Dose Modifications
- Do not re-escalate the Kadcyla dose after a dose reduction is made.
- If a planned dose is delayed or missed, administer as soon as possible; do not wait until the next planned cycle. Adjust the schedule of administration to maintain a 3-week interval between doses. Administer the infusion at the dose and rate the patient tolerated in the most recent infusion.
- Slow or interrupt the infusion rate of Kadcyla if the patient develops an infusion-related reaction. Permanently discontinue Kadcyla for life-threatening infusion-related reactions.
- Management of increased serum transaminases, hyperbilirubinemia, left ventricular dysfunction, thrombocytopenia, pulmonary toxicity or peripheral neuropathy may require temporary interruption, dose reduction or treatment discontinuation of Kadcyla.
Health News
- Scans Show Brain Changes in People With Long COVID
- Got GERD? Eat This Way to Help Avoid Symptoms
- 5 Women Contracted Syphilis Affecting the Eyes From the Same Asymptomatic Man
- Long COVID Now Common in U.S. Nursing Homes
- Breathing in Coal-Based Pollution Could Be Especially Deadly: Study
More Health News ยป
Is Kadcyla safe to use while pregnant or breastfeeding?
Embryo-Fetal Toxicity
- Advise pregnant women and females of reproductive potential that Kadcyla exposure during pregnancy or within 7 months prior to conception can result in fetal harm. Advise female patients to contact their healthcare provider with a known or suspected pregnancy.
- Advise women who are exposed to Kadcyla during pregnancy or who become pregnant within 7 months following the last dose of Kadcyla that there is a pregnancy pharmacovigilance program that monitors pregnancy outcomes. Encourage these patients to report their pregnancy to Genentech.
- Advise females of reproductive potential to use effective contraception during treatment and for 7 months following the last dose of Kadcyla.
- Advise male patients with female partners of reproductive potential to use effective contraception during treatment and for 4 months following the last dose of Kadcyla.
Lactation
- Advise women not to breastfeed during treatment and for 7 months after the last dose of Kadcyla.
Summary
Kadcyla (ado-trastuzumab emtansine) is a second- or third-line chemotherapy treatment for HER-2 breast cancers. It's used in combination with other drugs or on its own after other drugs have failed.
Multimedia: Slideshows, Images & Quizzes
-
Breast Cancer Awareness: Symptoms, Diagnosis, and Treatment
Learn about breast cancer causes, symptoms, tests, recovery, and prevention. Discover the types of treatments such as surgery and...
-
10 Things Young Women Should Know About Breast Cancer
Is breast cancer genetic? Should I get tested for the BRCA gene? What every young women should know about breast cancer. Discover...
-
Breast Cancer Quiz: Symptoms & Signs
This Breast Cancer Quiz features signs, symptoms, facts, causes, common forms, terms, risk factors, statistics, and more. ...
-
Breast Cancer: Where It Can Spread
When breast cancer spreads, or metastasizes, it often goes to these five places: the lymph nodes, bones, liver, lungs, and brain....
Related Disease Conditions
-
Breast Cancer in Men
Second Source WebMD Medical Reference
-
Breast Cancer
Breast cancer is an invasive tumor that develops in the mammary gland. Breast cancer is detected via mammograms, breast self-examination (BSE), biopsy, and specialized testing on breast cancer tissue. Treatment of breast cancer may involve surgery, radiation, hormone therapy, chemotherapy, and targeted therapy. Breast cancer risk may be lowered by managing controllable risk factors. What you should know about breast cancer Breast cancer is the most common cancer among American women. One in every eight women in the United States develops breast cancer. There are many types of breast cancer that differ in their capability of spreading (metastasize) to other body tissues. The causes of breast cancer are unknown, although medical professionals have identified a number of risk factors. There are 11 common types of breast cancer and 4 uncommon types of breast cancer. Breast cancer early signs and symptoms include a lump in the breast or armpit, bloody nipple discharge, inverted nipple, orange-peel texture or dimpling of the breast's skin (peau d'orange), breast pain or sore nipple, swollen lymph nodes in the neck or armpit, and a change in the size or shape of the breast or nipple. Breast cancer can also be symptom free, which makes following national screening recommendations an important practice. Breast cancer is diagnosed during a physical exam, by a self-exam of the breasts, mammography, ultrasound testing, and biopsy. Treatment of breast cancer depends on the type of cancer and its stage (0-IV) and may involve surgery, radiation, or chemotherapy.
-
Triple-Negative Breast Cancer
Triple-negative breast cancer is more common in Hispanic and African-American women. Signs and symptoms include a lump in the armpit or breast, nipple discharge and inversion, and changes in the breast's skin. Treatment may incorporate surgery, chemotherapy, and radiation therapy.
-
Can Fibroadenomas Turn Into Breast Cancer?
A fibroadenoma is the most common type of benign, non-cancerous lump of the breast. Although it is rare, complex fibroadenomas and phyllodes tumors have a chance to develop into malignant breast cancer.
-
Inflammatory Breast Cancer
Inflammatory breast cancer is an accelerated form of breast cancer that is not usually detected by mammogram or ultrasound. Symptoms of inflammatory breast cancer include pain in the breast, skin change in the breast area, bruise on the breast,sudden swelling of the breast, nipple retraction or discharge, and swelling of the lymph nodes.
-
Breast Cancer Prevention
Lifestyle changes, a healthy antioxidant-rich diet, exercise, and weight reduction can help reduce a woman's risk of developing breast cancer. It's important to be aware of how risk factors such as family history, lifestyle factors, breast conditions, radiation therapy, and hormonal factors may influence your chances of developing breast cancer. Mammography and breast self-examinations are crucial steps in breast cancer prevention.
-
Breast Cancer and Coping With Stress
Being diagnosed with breast cancer is stressful. Learning relaxation techniques, exercising, eating well, getting adequate sleep, receiving psychotherapy, and maintaining a positive attitude can help you cope. Creating documents, such as an advance directive, living will, and durable power of attorney will outline your wishes in the event that you are no longer able to make decisions regarding your care.
-
Breast Cancer and Lymphedema
Lymphedema is a common chronic, debilitating condition in which excess fluid called lymph collects in tissues and causes swelling in them. It is common after a mastectomy, lumpectomy or breast cancer surgery and radiation therapy.
-
Breast Cancer Recurrence
Breast cancer most often recurs within the first 3-5 years after the initial treatment. Changes in the look, feel, or appearance of the breast may indicate breast cancer recurrence. Factors related to recurrence include tumor size, tumor grade, hormone receptor status, lymph node involvement, and oncogene expression. Check out the center below for more medical references on breast cancer, including multimedia (slideshows, images, and quizzes), related diseases, treatment, diagnosis, medications, and prevention or wellness.
-
Breast Cancer Stages
Breast cancer staging is the determination of the extent and spread of cancer. An individual's health care team uses stages to summarize the extent of cancer in a standardized way that is recognized by all health care providers. They use this staging to determine the treatment most appropriate for the type of cancer. Cancer staging helps to determine the prognosis, or outlook, of cancer, including rates of recurrence and survival rates.
-
HER2-Positive Breast Cancer
In about 10%-20% of breast cancers, the cancer cells test positive for HER2, sometimes referred to as the HER2/neu protein. HER2 is a growth-promoting protein located on the surface of some cancer cells. HER2-positive breast cancers tend to grow more rapidly and spread more aggressively than breast cancers that are HER2-negative. Doctors do not know what specifically causes some breast cancers to express this protein while others do not.
-
Breast Cancer Early Warning Signs and Symptoms
In most cases, there are no early warning signs of breast cancer. Breast cancer may not produce any early symptoms, and in many cases, it is first discovered on screening mammography. The most common sign of breast cancer is a new lump or mass in the breast.
-
What Is Usually the First Sign of Breast Cancer?
A lump in the breast or in the armpits is often the first sign of breast cancer. This may be felt while in the shower. There may or may not be changes in the structure of the breast. Other early signs include changes in breast skin, breast pain and others.
-
Breast Cancer Treatment
Breast cancer treatments depend upon the type of breast cancer that is present as well as the stage (extent of spread) of the tumor. Treatment for early breast cancer typically involves surgery to remove the tumor. After surgery, medical professionals may administer radiation therapy, chemotherapy, or targeted therapy.
-
What Is the Breast Cancer BRCA Gene Test?
BRCA genes (BRCA 1 and 2, when normal, repair damaged DNA) are among the genetic mutations linked to breast cancer, ovarian cancer, and other cancers when mutated. Every woman with a BRCA mutation is at high risk for breast cancer, irrespective of whether she has a family history of breast cancer or not. By age 80, a woman with a BRCA mutation has about an 80% chance of developing breast cancer. BRCA1 and BRCA2 gene mutations also increase the risk of ovarian cancer, by 54% and 23%, respectively.
-
What Questions Should I Ask My Doctor About Breast Cancer?
A diagnosis of breast cancer can be overwhelming, so it's important to write down all your questions before meeting with your doctor.
-
What Should I Know About Breast Cancer?
Breast cancer is the most common non-skin cancer of American women, but it can also occur in men. Every year in the U.S., there are over 266,000 new diagnoses of breast cancer. A woman has a risk of one in eight for developing breast cancer at some point during her lifetime.
-
Breast Cancer Treatment by Stage
Treatment of breast cancer depends upon the stage of the cancer at the time of diagnosis. Some of the various treatments include: hormone therapy, radiation therapy, surgery, chemotherapy, HER2-targeted therapy, neoadjuvant therapy, and adjuvant therapy.
-
What Are The Five Warning Signs Of Breast Cancer?
The majority of breast cancer patients first seek diagnosis because of a lump on the breast. This is one of the five warning signs of breast cancer. Others include changes in the nipple, changes in the breast skin and other symptoms.
-
What Are the Four Types of Breast Cancer?
The four most common types of breast cancer are ductal carcinoma in situ, lobular carcinoma in situ, invasive ductal carcinoma, invasive lobular carcinoma. The designations are based on the locations of the tumors, whether they have spread and where they have spread to.
-
Breast Cancer in Young Women
About 5% of cases of breast cancer occur in women under the age of 40 years old. Some risk factors for breast cancer in young women include a personal history of breast cancer or breast disease, family history of breast cancer, prior radiation therapy, and the presence of BRCA1/BRCA2 gene mutations. Breast self-exams, clinical breast exams, and screening mammograms may help detect breast cancer. Treatment may include surgery, chemotherapy, radiation, and hormone therapy.
-
Breast Cancer Clinical Trials
Breast cancer clinical trials are research programs designed to evaluate new medical treatments, drugs, or devices for the treatment of breast cancer. Clinical trials are designed to test the safety and efficacy of new treatments as well as assess potential side effects. Clinical trials also compare new treatment to existing treatments to determine if it's any better. There are many important questions to ask your doctor before taking part in a breast cancer clinical trial.
-
Breast Cancer During Pregnancy
Breast cancer occurs in about 1 in every 1,000 pregnant women. Treatment of breast cancer during pregnancy involves surgery, but it is very difficult to protect the baby from the dangerous effects of radiation and chemotherapy. It can be an agonizing to decide whether or not to undergo breast cancer treatment while one is pregnant.
-
Breast Cancer Growth Rate
The available evidence suggests that breast cancer may begin to grow around 10 years before it is detected. However, the time for development differs from tumor to tumor.
-
How Can You Detect Breast Cancer Early?
Breast cancer develops from the cells of the breasts and can spread to other parts of the body (metastasis). It is one of the most common cancers diagnosed in women in the United States. A lump in the breast or armpit is often the first sign. Treatment success depends largely on early detection.
-
Genetic Testing: Families With Breast Cancer
Breast cancer can be a killer and the decision to get tested to see if a patient is prone to the disease should be discussed with a doctor -- particularly if the woman has a history of breast cancer in her family. Genetic testing can only tell so much about breast cancer risk, however.
Treatment & Diagnosis
- Breast Cancer FAQs
- Breast Cancer Risk - Reduced With Exercise
- Herceptin Metastatic Breast Cancer Treatment
- Breastfeeding -- Protection from Breast Cancer?
- Hormone Therapy in Survivors of Breast Cancer
- Breast Cancer: Types of Breast Cancer
- Elizabeth Edwards has Breast Cancer Alert
- Exercise Improves Breast Cancer Survival
- Stress and Aggressive Breast Cancer: Cause or Effect?
- Advanced Breast Cancer in Young Women Increasing
- Angelina Jolie's Mastectomy
- Does Positive Additude Affect Breast Cancer?
- How Common and Dangerous Is Male Breast Cancer?
- How Many Breast Cancer Deaths Are there Each Year?
- Where Can Breast Cancer Spread To?
- Why Is Breast Cancer More Common in Females than Males?
- How Much Breast Cancer is Genetic?
- How Long Can Breast Cancer Patients Live?
- Who Does Breast Cancer Affect?
- How Does Breast Cancer Form?
- How Many Breast Cancer Stages Are There?
- Facts on Breast Cancer Causes, Risk Factors, and Types
- Breast Cancer Symptoms and Signs
- Breast Cancer Detection
- Breast Cancer Treatment
Medications & Supplements
Prevention & Wellness
Subscribe to MedicineNet's Cancer Report Newsletter
By clicking "Submit," I agree to the MedicineNet Terms and Conditions and Privacy Policy. I also agree to receive emails from MedicineNet and I understand that I may opt out of MedicineNet subscriptions at any time.
Health Solutions From Our Sponsors

Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.